Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
XYF-19 by Xi'An Yufan Biotechnology for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
XYF-19 is under clinical development by Xi'An Yufan Biotechnology and currently in Phase I for Acute Lymphocytic Leukemia (ALL, Acute...
XYF-19 by Xi'An Yufan Biotechnology for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval
XYF-19 is under clinical development by Xi'An Yufan Biotechnology and currently in Phase I for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According...
XYF-19 by Xi'An Yufan Biotechnology for Mantle Cell Lymphoma: Likelihood of Approval
XYF-19 is under clinical development by Xi'An Yufan Biotechnology and currently in Phase I for Mantle Cell Lymphoma. According to...
XYF-19 by Xi'An Yufan Biotechnology for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
XYF-19 is under clinical development by Xi'An Yufan Biotechnology and currently in Phase I for Diffuse Large B-Cell Lymphoma. According...
XYF-19 by Xi'An Yufan Biotechnology for Hairy Cell Leukemia: Likelihood of Approval
XYF-19 is under clinical development by Xi'An Yufan Biotechnology and currently in Phase I for Hairy Cell Leukemia. According to...
XYF-19 by Xi'An Yufan Biotechnology for Burkitt Lymphoma: Likelihood of Approval
XYF-19 is under clinical development by Xi'An Yufan Biotechnology and currently in Phase I for Burkitt Lymphoma. According to GlobalData,...
XYF-19 by Xi'An Yufan Biotechnology for Marginal Zone B-cell Lymphoma: Likelihood of Approval
XYF-19 is under clinical development by Xi'An Yufan Biotechnology and currently in Phase I for Marginal Zone B-cell Lymphoma. According...
XYF-19 by Xi'An Yufan Biotechnology for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
XYF-19 is under clinical development by Xi'An Yufan Biotechnology and currently in Phase I for Chronic Lymphocytic Leukemia (CLL). According...